Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lineage Cell Therapeutics, Inc. LCTX

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for...


Recent & Breaking News (NYSEAM:LCTX)

Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss

Business Wire March 21, 2022

RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS

Business Wire March 14, 2022

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Business Wire March 10, 2022

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 10, 2022

Business Wire March 1, 2022

Lineage to Present at B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022

Business Wire January 24, 2022

Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference

Business Wire January 4, 2022

Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders

Business Wire December 20, 2021

Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®

Business Wire November 30, 2021

OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D.

Business Wire November 15, 2021

Lineage Reports Third Quarter 2021 Financial Results and Highlights Progress From Clinical Cell Therapy Programs

Business Wire November 10, 2021

Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, 2021

Business Wire November 3, 2021

OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D.

Business Wire October 26, 2021

Lineage to Be Featured in B. Riley Securities Fall 2021 "Growth Biotech Best Ideas" Virtual Series on October 18, 2021

Business Wire October 18, 2021

Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

Business Wire September 30, 2021

Lineage to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021

Business Wire September 20, 2021

Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy

Business Wire September 15, 2021

Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

Business Wire September 13, 2021

Lineage Announces Appointment of General Counsel

Business Wire September 1, 2021

Brooklyn ImmunoTherapeutics Completes Reverse Merger with NTN Buzztime

Business Wire March 25, 2021

BioTime Reports Second Quarter 2019 Financial Results and Provides Business Update

Business Wire August 8, 2019